Emergent BioSolutions Inc. (NYSE:EBS) and Valneva SE (Euronext Paris:VLA) today announced the initiation of a Phase 1 clinical trial in the U.S. to evaluate the safety and immunogenicity of VLA1601, their vaccine candidate against Zika virus.
SUBSCRIBE
Biohealth Innovation
Founding Member of
